Proteomic analysis of serum associated fucosylated glycoproteins in the development of primary hepatocellular carcinoma

被引:176
作者
Comunale, MA
Lowman, M
Long, RE
Krakover, J
Philip, R
Seeholzer, S
Evans, AA
Hann, HWL
Block, TM
Mehta, AS [1 ]
机构
[1] Drexel Univ, Coll Med, Dept Microbiol & Immunol, Drexel Inst Biotechnol & Virol Res, Doylestown, PA 18901 USA
[2] Penn Commonwealth Inst, Inst Virus & Hepatitis Res, Doylestown, PA 18901 USA
[3] Immunotope Inc, Doylestown, PA 18901 USA
[4] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA
[5] Thomas Jefferson Univ, Div Gastroenterol & Hepatol, Philadelphia, PA 19107 USA
关键词
hepatocellular carcinoma; fucosylation; glycomics; biomarkers;
D O I
10.1021/pr050328x
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Changes in N-linked glycosylation are known to occur during the development of cancer. For example, increased branching of oligosaccha rides has been associated with metastasis and has been correlated to tumor progression in human cancers of the breast, colon and melanomas. Increases in core fucosylation have also been associated with the development of hepatocellular carcinoma (HCC). Chronic infection with the hepatitis B virus is associated with more than 55% of all cases of hepatocellular carcinoma. We show here that increased levels of core fucosylation can be observed via glycan analysis of total serum and are associated with the development of HCC. In a blinded study, the serum glycoproteins derived from people diagnosed with HBV induced liver cancer were found to possess a dramatically higher level of fucosylation. This change occurs on both immunoglobulin molecules and on other serum glycoproteins. Targeted glycoproteomic analysis was used to identify those glycoproteins that are hyperfucosylated in cancer. In total, 19 proteins were found to be hyperfucosylated in cancer. The potential of these proteins as biomarkers of cancer is discussed.
引用
收藏
页码:308 / 315
页数:8
相关论文
共 33 条
[1]  
Aoyagi Y, 1998, CANCER, V83, P2076, DOI 10.1002/(SICI)1097-0142(19981115)83:10<2076::AID-CNCR5>3.0.CO
[2]  
2-L
[3]  
BEASLEY RP, 1988, CANCER, V61, P1942, DOI 10.1002/1097-0142(19880515)61:10<1942::AID-CNCR2820611003>3.0.CO
[4]  
2-J
[5]  
BENVEGNU L, 1994, CANCER, V74, P2442, DOI 10.1002/1097-0142(19941101)74:9<2442::AID-CNCR2820740909>3.0.CO
[6]  
2-#
[7]   Use of targeted glycoproteomics to identify serum glycoproteins that correlate with liver cancer in woodchucks and humans [J].
Block, TM ;
Comunale, MA ;
Lowman, M ;
Steel, LF ;
Romano, PR ;
Fimmel, C ;
Tennant, BC ;
London, WT ;
Evans, AA ;
Blumberg, BS ;
Dwek, RA ;
Mattu, TS ;
Mehta, AS .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (03) :779-784
[8]   HEPATITIS-B VIRUS (HBV) AND HEPATOCELLULAR-CARCINOMA - HBV DNA STATUS AND ITS IMPLICATIONS [J].
BRECHOT, C .
JOURNAL OF HEPATOLOGY, 1987, 4 (02) :269-279
[9]   Hepatitis B and C viruses and primary liver cancer [J].
Brechot, C .
BAILLIERES CLINICAL GASTROENTEROLOGY, 1996, 10 (02) :335-373
[10]   SERUM-ALPHA-FETOPROTEIN HETEROGENEITY AS A MEANS OF DIFFERENTIATING BETWEEN PRIMARY HEPATOCELLULAR-CARCINOMA AND HEPATIC SECONDARIES [J].
BUAMAH, PK ;
GIBB, I ;
BATES, G ;
WARD, AM .
CLINICA CHIMICA ACTA, 1984, 139 (03) :313-316